Department of Sense Organs, University Sapienza of Rome, Viale del Policlinico, 155, 00161, Rome, Italy.
Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy.
Graefes Arch Clin Exp Ophthalmol. 2022 Mar;260(3):917-925. doi: 10.1007/s00417-021-05431-6. Epub 2021 Oct 11.
Neurotrophic keratopathy (NK) is a degenerative corneal disease caused by damage of trigeminal innervation. The purpose of this study is to evaluate the clinical outcomes and patient-reported satisfaction of treatment with amniotic membrane transplantation (AMT) or cenegermin eye drops in patients with NK.
Clinical charts of patients with NK treated with AMT (group A) or cenegermin eye drops (group B), with at least 12 months of follow-up, were reviewed for demographics, medical history, corneal healing, and disease recurrence. Patient satisfaction was evaluated by a newly developed questionnaire investigating patient's appreciation of treatment of NK (2 items) and satisfaction with NK treatment outcomes (5 items).
At the end of treatment, complete corneal healing was observed in 13/15 (86%) patients in group A and in 23/24 (96%) in group B. At 12 months follow-up, 6/13 patients (46%) in group A and 3/23 patients (13%) in group B showed recurrence of NK (p = 0.037). Survival analysis showed that group B remained recurrence free for a significantly longer period of time than the group A (p = 0.028). Patients in group B showed a significantly higher satisfaction when compared with patients in group A (total score: 65.7 ± 15.7 vs 47.4 ± 12.8, p = 0.003), both in terms of patients' appreciation of treatment (78.3 ± 15.9 vs 52.2 ± 30, p = 0.020) and satisfaction with treatment outcomes (60.7 ± 21 vs 45.4 ± 13.3, p = 0.037).
Treatment of NK with cenegermin was associated with long-term maintenance of corneal integrity and a higher degree of patient satisfaction.
神经退行性角膜病变（NK）是一种由三叉神经支配损伤引起的退行性角膜疾病。本研究旨在评估羊膜移植（AMT）或重组人神经生长因子（rhNGF）眼液治疗 NK 患者的临床效果和患者满意度。
回顾性分析了 15 例（A 组）和 24 例（B 组）接受 AMT 或 rhNGF 治疗、随访至少 12 个月的 NK 患者的临床资料，包括人口统计学、病史、角膜愈合和疾病复发情况。采用新开发的问卷评估患者对 NK 治疗的满意度（2 项）和对 NK 治疗结果的满意度（5 项）。
治疗结束时，A 组 13/15 例（86%）患者和 B 组 23/24 例（96%）患者完全愈合。12 个月随访时，A 组 6/13 例（46%）患者和 B 组 3/23 例（13%）患者 NK 复发（p=0.037）。生存分析显示，B 组无复发时间明显长于 A 组（p=0.028）。与 A 组相比，B 组患者的满意度明显更高（总分：65.7±15.7 比 47.4±12.8，p=0.003），包括对治疗的满意度（78.3±15.9 比 52.2±30，p=0.020）和对治疗结果的满意度（60.7±21 比 45.4±13.3，p=0.037）。
rhNGF 治疗 NK 可长期保持角膜完整性，患者满意度更高。
